Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by gitchie1on Nov 20, 2010 10:29pm

885 Views

Post# 17735357

RE: RE: rvx selling off to big pharma

come to think of it he told me he turned down an offer 2 years ago for 20us per share but that was over a 6 pack each and I had just beat him in pool.You cant ignore the science.im staying in for the whold ride.i missed the run up to 27.00 a few years back.sold at 11.00 and 3 weeks later was 27.then the long slide down when i rebuy to hit the motherload!!

Bullboard Posts

Visionstate set to leverage success in the U.S. market